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 A solvent detergent treated fibrinogen was purified from human plasma by 
cryoprecipitation (cryo) followed by chemical precipitation using ethanol (EtOH) or 
ammonium sulfate (AS) as precipitating agents. Amounts of fibronectin (FN), factor XIII 
A-subunit (FXIIIA), factor XIII b-subunit (FXIIIB), and alpha2-antiplasmin (α2-AP) in 
the isolated fibrinogen were quantified. Thromboelastography (TEG) analysis was used 
to evaluate the clot strength of the isolated fibrinogen and to determine the ability of the 
ethanol and ammonium sulfate precipitations to eliminate the solvent detergent. Sodium 
dodecylsulfate-polyacrylamide gel analysis indicated that fibrinogen produced by each of 
these precipitation methods had similar purity. Quantitative western blot analysis 
revealed that fibrinogen produced by ammonium sulfate precipitation contained increased 
amounts of FN, FXIIIB, and α2-AP. TEG analysis showed that ammonium sulfate 
precipitated fibrinogen yielded a fibrin clot with the highest maximal strength. In 
addition, a single ethanol precipitation was sufficient to remove the solvent detergent 
while a single ammonium sulfate precipitation was not effective in removing the solvent 
detergent mixture Tri (n-butyl) phosphate (TNBP) and Triton X-100 as judged by the 
ability of the material to form a clot.  
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INTRODUCTION 
  
Fibrinogen 
 
Fibrinogen (FI) is a central molecule in the blood coagulation cascade that is 
transformed by thrombin into fibrin which polymerizes forming a clot to prevent the loss 
of blood at the site of vascular injury. Furthermore, because it has multiple binding sites 
that can react with other proteins, fibrinogen plays important roles in many physiological 
and pathological processes including blood clotting, fibrinolysis, cell adhesion, 
inflammation, angiogenesis, atherogenesis, tumorigenesis, and wound healing [1]. 
Fibrinogen is a 340 kDa glycoprotein consisting of two identical subunits, each of which 
is made of three polypeptide chains termed Aα, Bβ, and γ [2]. The three chains of 
fibrinogen differ in terms of their structures and functions [Table 1]. 
A series of disulfide bonds link fibrinogen polypeptide chains forming elongated 
45 nm tri-nodular structures with distinct domains. These domains are arranged into three 
main structural regions: a central E, two distal D and the αC regions [3-5]. The central E 
nodule is formed by the N-terminal portions of the six polypeptide chains. The distal D 
nodules, formed by the C-terminal portions of the Bβ and γ as well as a fraction of the Aα 
chains, are separated from the E region by coiled-coil regions [6, 7]. The C-terminal 
region of the Aα-chain extends out from the D domains and is called the αC domains [8]. 
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Table 1: Properties of fibrinogen chains 
 α-chain β-chain γ-chain 
Molecular Weight 
[9] 
67 KDa 54 KDa 47 KDa  
Amino Acids [2] 610 461 411 
Fibrinopeptide  FpA FpB None  
Carbohydrate 
[10,11] 
None 2 oligosaccharide 2 oligosaccharide 
  
Based on the composition of the γ-chain, human fibrinogen can be isolated into 
two major fractions, fibrinogen-1 and fibrinogen-2 [12, 13]. Fibrinogen-1 possesses two 
homo-dimeric γ-chains each composed of 411 amino acids while fibrinogen-2 contains 
two hetero-dimeric molecules one γ-chain and one γ -chain [12, 14]. The γ -chain 
accounts for 15% of plasma fibrinogen and is formed by the alternative processing at the 
exon 9-exon 10 boundaries of the primary mRNA transcript [15]. The inclusion of intron 
9 in the messenger results in the replacement of 4 amino acids (AGDV) of the γ-chain 
with a 20 amino acid sequence that contains two sulfated tyrosines and several Asp and 
Glu residues. Therefore, the γ -chain is longer and contains more anion groups than the γ-
chain [16, 14]. 
Fibrinogen has the ability to react with numerous substances with important 
physiological consequences. For example, The C-terminal of the Aα-chain (αC domains) 
of fibrinogen has binding sites for α2-AP, plasminogen, tissue-type plasminogen activator 
(tPA), and PAI-2. Table 2 lists binding sites and physiological roles of some fibrinogen-
protein interactions. 
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Table 2: Fibrinogen binding Ligands 
Ligands Binding Site Function 
Fibronectin [17] 
FGF-2, bFGF [18] 
Lipoprotein (a) [19, 20] 
Aα-chain  
- 
 
Aα-chain 
Cell adhesion 
Proliferation of endothelial 
cells 
Inhibit fibrinolysis 
Thrombin [21] 
Plasminogen [22] 
 
FXIII [23-25] 
 
α2-AP [26] 
 
Integrin [2] 
 
Calcium [27]          
γ -chain 
Aα-chain 
 
γ -chain 
 
Aα-chain 
 
Aα-chain 
 
Bβ and γ-chains                                                                            
 
Fibrinopeptide release 
Enhance fibrinolysis 
Stabilizing clot 
Resist fibrinolysis 
Cellular interactions 
Promote polymerization
 
Human fibrinogen heterogeneity results from modification at several different 
sites both during and after biosynthesis. The heterogeneity arises from alternative splicing 
[28], alteration of different amino acids by sulfation [29], phosphorylation [30], various 
degrees of glycosylation [31], proteolysis [32], and some genetic polymorphisms [33]. 
These mechanisms form over a million species of fibrinogen [34].These heterogeneities 
can change fibrin matrix properties thus helping to explain the difference that exist 
between individuals and wound healing.   
During coagulation, thrombin converts soluble fibrinogen into fibrin monomers, 
which then polymerize to form a network of fibrin fibers. This network is stabilized by 
thrombin activated FXIII to form an insoluble fibrin clot. Formation of fibrin begins 
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when thrombin binds to a substrate site in fibrinogen and cleaves fibrinopeptides A (FpA) 
and B (FpB) from the amino termini of the Aα and Bβ chains, respectively. The removal 
of FpA exposes the polymerization site “A” that contains the N-terminal sequence (Gly-
Pro-Arg-Val) of the Aα-chain, while the removal of FpB exposes the polymerization site 
“B” that contains the N-terminal sequence of the Bβ-chain [35]. The polymerization site 
“A” interacts with the complementary binding site of the γ-chain, whereas the 
polymerization site “B” interacts with the complementary binding site of the β chain [36]. 
These interactions lead to the formation of half-staggered, double-stranded protofibrils 
that undergo lateral aggregation to form fibers [37]. Thrombin simultaneously converts 
factor XIII (FXIII) to the active form (FXIIIa) which catalyzes formation of covalent ε-
(γ-glutamyl) lysine bonds between adjacent fibrin molecules [37-40]. The cross-linking 
occurs rapidly between Lys-406 of one γ-chain and Gln-398 of another γ-chain to form γ-
dimers [41, 42, 25]. In addition, hetero-dimers cross-linked α-γ have been found in 
plasma fibrinogen [43]   
Different techniques have been developed for the purification of fibrinogen from 
plasma materials. Cryoprecipitation is the most common method for isolating fibrinogen, 
which reduces the solubility of fibrinogen at lower temperature to prevent its 
denaturation. Compared to fresh frozen plasma, cryoprecipitate contains an increased 
percentage of fibrinogen. Cryoprecipitation involves freezing the citrated plasma at lower 
temperature, usually -20 °C or less for at least 12 hours. The frozen plasma is slowly 
thawed at 4 °C followed by centrifugation to isolate the fibrinogen precipitate. The 
concentration of fibrinogen produced by cryoprecipitation is between 8 to 30 mg/ml and 
5 
 
can be increased to 40 to 60 mg/ml using repeated freeze/thaw cycles [44]. An 
ultrafiltration procedure has been used to purify fibrinogen where platelet rich plasma is 
separated using an ultrafiltration chamber with a molecular weight cutoff of 30 kDa. 
Fibrinogen obtained using this method has a final concentration of 6 mg/ml and lower 
clottability due to large amount of fibrinogen being denatured [45]. Fibrinogen has also 
been isolated from human plasma by using chemical precipitation methods in which 
chemical agents such as ethanol, glycine, β-alanine, ether, or ammonium sulfate are used 
to precipitate fibrinogen from plasma [46-49]. 
The clinical use of fibrinogen from pooled human plasma has been previously 
associated with a high risk of transmission of plasma–borne infectious species such as 
HIV, HBV, and HCV. The improvements in viral testing and screening have reduced, but 
not eliminated this risk. Therefore, different techniques have been developed in order to 
inactivate pathogenic viruses in fibrinogen derived from human plasma. Dry heat 
treatment at 60-68 °C of plasma cryoprecipitate inactivates HIV but it does not prevent 
the transmission of HCV [50]. Plasma pathogens have been inactivated by treating fresh 
plasma with methylene blue followed by exposure to visible light. This approach is less 
effective versus non-enveloped viruses and results in approximately 20% fibrinogen loss 
[51]. Solvent detergent (SD) treatment is the most effective procedure for inactivating 
blood-borne lipid-enveloped viruses. Solvent detergent treatment inactivates viruses by 
dissolving their lipid envelope but it does not inactivate non-lipid enveloped viruses such 
as parvovirus or hepatitis A virus [50].  The treatment of cryoprecipitate with a 
combination of organic solvent, tri (n-buty1) phosphate (TNBP), and detergent (sodium 
cholate, Tween 80, or Triton X-100) has been shown to inactivate very large quantities of 
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HBV, HCV, and HIV while preserving the activity of the purified protein. Radosevich et 
al [52] showed that treating cryoprecipitate with a mixture of 0.3% TNBP and 1% tween 
80 at 25 °C for 6 hours inactivated   5.5 log10 of HIV,   5 log10 of VSV virus, and   6.5 
log10 of sindbis virus. Horowitz and coworkers [53] revealed that subjecting pooled 
plasma to a mixture of 1% TNPB and 1% Triton X-100 for 4 hours at 30 °C inactivates   
10
6
 CID50 of HBV, 
 
10
5
 CID50 of HCV, and 10
6.2
 TCID50 of HIV. 
Factor XIII 
 
Factor XIII, activated in the latter stages of the blood coagulation cascade, is a 
pro-transglutaminase that exists naturally in an intracellular or plasma form [54, 55]. The 
plasma form is a tetramer composed of two A-subunits (FXIIIA) and two B-subunits 
(FXIIIB) with a molecular mass of  83 and ~80 kDa respectively [56]. Structural 
investigation of the tetramer indicates that the two A-subunits are globular proteins 
surrounded by two long flexible B-subunits [57, 58]. There are non-covalent interactions 
between the two A-chains and appears to be a non-covalent bond between the A and B 
[59]. The A-subunit contains the active site of the enzyme while the B-subunit serves to 
transport and protect the catalytic A-subunit until it is required in catalysis [60, 61]. 
Under normal conditions, the human plasma concentration of FXIII is ~14 to 28 mg/L 
[62]. Whereas carbohydrate accounts for approximately 8.5% of the total molecular 
weight of FXIIIB, the FXIIIA contains no carbohydrate [Table 3]. 
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Table 3: Characteristics of FXIII subunits 
 A-subunit B-subunit 
Molecular weight [56] 83 kDa 80 kDa  
Residues [63, 64] 731 641 
Carbohydrate [65] None  ~8.5% of the total weight 
N-terminal [59] Acetylated serine  Glutamic acid 
Disulfide bonds [63] None 20 
Structure [64] Globular Kinked strand 
Function [66]  Catalyzes an acyl transfer 
reaction 
Acts as a carrier for  
A-subunit 
Secreted by [66] Liver, monocytes 
and megakaryocytes 
Liver 
Active site [66] Cys314 None  
 
The primary structure of FXIII subunits has been determined through the aid of 
amino acid sequence analysis and cDNA cloning. The A-subunit is made of five distinct 
folded domains: an activation peptide of 37 amino residues that is cleaved off during 
thrombin activation of the enzyme, a β-sandwich containing residues 38-183, a catalytic 
core composed of residues 184-515, and two barrels comprised of residues 516-627 and 
628-731, respectively [66]. While the catalytic core consists of both α-helices and β-
sheets, the β-sandwich and barrel domains contain only β-sheets [Fig 1]. There are 
several hydrogen bonds and salt bridges between the β-sandwich, the activation peptide, 
and the catalytic core of the first subunit with the β-barrel and catalytic core of the second 
subunit [67]. These non-covalent interactions help stabilize the overall structure. 
Although FXIIIA possesses nine cysteine residues, no disulfide bridges have been 
detected in the subunit. There are six potential N-glycosylation sites in FXIIIA but no 
carbohydrate residue has been found in the secondary structure [65].  
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FXIIIB is a modular protein built from 10 repetitive sushi domains. Each sushi 
domain contains approximately 60 amino acids held together by two disulfide bridges 
forming a β-sandwich tertiary structure [63]. Employing electron microscopy and 
sedimentation techniques, the B-subunit appears as a thin, flexible strand with random 
kinks whereas unbound FXIIIB appears as a monomeric structure [64].  
While plasma FXIII (pdFXIII) circulates as a tetramer, intracellular FXIII is a 
dimer composed of two A-subunits (FXIIIA2) each containing 730 amino acid residues 
[68]. This dimeric molecule has a molecular weight of approximately 160 kDa and 
mainly found in platelets, monocytes, and megakaryocytes [68, 63]. The primary 
structure of cellular FXIII is identical to plasma FXIIIA and the two molecules share the 
same immunochemical and electrophoretic properties  
FXIIIA catalyzes an acyl transfer reaction where glutamine residues serve as an 
acyl donor. This reaction proceeds through acylation and de-acylation intermediate steps 
to form an amide bond between  -carbonyl group of glutamine and  -amino group of 
lysine [69]. Compared to other transglutaminase family members, FXIIIA has more 
restricted substrate specificity.   
In the final stage of the blood coagulation cascade, the serine protease thrombin 
activates either form of FXIII in the presence of Ca
2+
. The activation sequence begins 
when thrombin hydrolyzes the peptide bond at Arg37-Gly38 releasing the activation 
peptide from the N-terminal region of the FXIII [69, 70] [Fig 1]. Studies using radio 
crystallography showed that the released activation peptide did not bind thrombin but 
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remained attached to the FXIII molecule preventing the access of the substrate to the 
active site [58]. The activation sequence proceeds when Ca
2+
 binds to either the free 
activation peptide or the zymogen. This binding induces a conformational change that 
leads to the dissociation of the activated A-subunits from the B-subunits. As a result, the 
active site Cys-314 that was originally shielded by the activation peptide becomes 
unmasked and available for reaction [60, 71].  
 
Figure 1: Schematic diagram illustrates FXIII activation in plasma. Removal 
of the activation peptide by thrombin weakens the binding of B-subunit to the truncated 
FXIIIA (  
   ). Conformational change induced by Ca
2+
 causes dissociation of    
    to 
generate FXIIIa [72].   
     
Except for the dissociation of the B-subunit step, intracellular FXIII activation by 
thrombin follows the same mechanism as extracellular FXIII. Activation of intracellular 
FXIII is faster since the B-subunit of plasma FXIII suppresses activation of cellular FXIII 
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by thrombin thereby down-regulating pdFXIII cross-linking of fibrinogen [73]. The 
presence of fibrin speeds up the activation of pdFXIII by approximately one hundredfold 
[71, 74]. This is because the adsorption of thrombin and pdFXIII onto the fibrin (ogen) 
surface orient these molecules in a way that favors the hydrolysis of the peptide bond at 
Arg37-Gly38 by thrombin. Therefore, fibrin facilitates the activation of extracellular 
FXIII while the absence of B-subunit from intracellular FXIII inhibits fibrin catalysis 
[74].  
The B-subunit of FXIII binds to the   -chain of fibrinogen thus heterodimeric 
fibrinogen (fibrinogen 2, γ/  ) serves as a carrier for FXIII in blood and also regulates its 
activity [75]. The presence of FXIII with fibrinogen in the plasma ensures that the 
formation of fibrin is associated with FXIII mediated cross-linking to generate a strong 
clot. FXIII cross-links homo-dimeric fibrinogen 1 molecules (γ/γ) 3.5 times faster than 
hetero-dimeric fibrinogen 2 molecules (γ/  ) indicating that fibrinogen 2 bound FXIII is 
essential for inhibiting FXIII mediated cross-linking activity in plasma [74]. Fibrinogen 
also reduces the amounts of calcium required to activate the truncated FXIIIA dimer 
(FXIII  
 
). Besides thrombin, there are several other serine proteases such as 
endogenous platelet acid and calpain that can also activate FXIII by cleaving the Arg37-
Gly38 peptide bond [76, 77].  
Besides fibrin and α2-antiplasmin, FXIIIA has many other potential substrate such 
as plasminogen, lipoprotein (a), plasminogen activator inhibitor type 2 (PAI-2), 
thrombin-activatible fibrinolysis inhibitor (TAFI), fibronectin, and many other proteins 
[Table 4]. 
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Table 4: FXIII substrates 
Substrate Cross-linking Site Cross-linking 
Targets 
Function 
α2-antiplasmin [78-
80] 
Gln2 Lys303 of α-chain Inhibit fibrinolysis 
Fibrin (ogen)  
α-chain [81-83] 
Gln221 and 237  
Lys208-Lys606 
Itself and γ-chains Clot stabilization 
Fibrin (ogen)  
γ-chain [23-25] 
Gln398, Gln399 and 
Lys406 
Itself and α-chains Clot stabilization 
Fibronectin [84, 85] Gln3 Itself, fibrin, and 
collagen 
Wound healing; 
migration of cells 
into the clot  
Collagen [84, 86] Gln3 Fibronectin, and 
fibrin 
Stabilization of 
extracellular matrix 
Von Willebrand 
Factor [87, 88] 
Gln3 Fibrin, collagen Platelet adhesion to 
the clot 
Vitronectin [89, 90] Gln93 Fibrin, collagen Platelet adhesion to 
the clot 
Factor V [91, 92] - - Increased thrombin 
generation at the colt 
surface 
Thrombospondin 
[93] 
- Fibrin Platelet adhesion to 
the clot 
Actin [94, 95] - Fibrin Clot reaction, 
stabilization of the 
platelet cytoskeleton 
TAFI [96] Gln2, Gln5, Gln292 Itself, fibrin Resistance to 
fibrinolysis 
PAI-2 [97, 98] - Lys148, Lys230, 
Lys413 of fibrin α-
chain 
Resistance to 
fibrinolysis 
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FXIII has important physiological roles in hemostasis, angiogenesis, wound 
healing, and pregnancy [99, 100]. Plasma FXIII, also known as fibrin stabilizing factor, is 
essential for preserving hemostasis by performing the following functions: Increasing clot 
strength by cross-linking fibrin; inhibiting fibrinolysis by cross-linking α2-antiplasmin to 
the α-chain of fibrin; inhibiting fibrinolysis by interfering with the adsorption of 
plasminogen into fibrin surface. FXIII is critical for creating a rigid, strong, and elastic 
clot needed to stop bleeding; therefore, FXIII deficiency results in severe bleeding [101-
104]. FXIII also plays a central role in the events that lead to wound healing such as 
fibroblast proliferation, attachment of cells to substrate, and in collagen formation [105]. 
Studies showed that FXIII-deficient individuals have lower fibroblast growth rate than 
patients with normal FXIII [105, 106].  FXIII activates a series of biochemical reactions 
that assist in cell adhesion and without FXIII cells lose their regular shape due to cell 
contact inhibition. In addition, collagen is not produced in the absence of FXIII which 
delays wound healing [107]. 
Recombinant FXIIIA (rFXIII), which has similar structure and function as FXIII-
A2, has been expressed in different cell types that include Escherichia coli [108], 
Sacharomyces cerevisiae [109, 110], and Schizosacharomyces pombe [111]. The 
numerous rFXIII crystal structures provided a wealth of information on catalytic activity 
as well as enzyme activation. Moreover, this structural information has been used to 
explain the consequences of some FXIII mutations [112]. 
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Alpha2-antiplasmin 
 
Human alpha2-antiplasmin is the primary physiological inhibitor of the blood 
fibrinolytic plasmin.  α2-AP is secreted by the liver as a single-chain glycoprotein of 464 
amino acid residues and molecular weight of ~70 kDa with  methionine as the N-
terminus (Met- α2AP) [113, 114]. The plasma concentration of α2-AP is ~70 µg/ml with a 
half-life of 2.6 days [115-117]. During circulation, Met-α2AP undergoes proteolytic 
cleavage between Pro12-Asn13 by circulating anti-plasmin cleaving enzyme (APCE), a 
proline-specific serine protease [118]. This results in the formation of a 452 amino acid 
derivative with N-terminal asparagine (Asn-α2AP). Asn-α2AP has a molecular weight of 
~64 KDa and accounts for 70% of the α2-AP in plasma while Met- α2AP accounts for the 
remaining 30% [113, 114]. Some properties of Met- α2AP and Asn- α2AP are listed in 
table 5. The human α2-AP gene is located on chromosome 17, specifically 17pter-p12 and 
17p13, and contains 10 exons and 9 introns [119]. The complete primary structure of 
human α2-AP has been deduced from the sequence of its cDNA. 
Human α2-antiplasmin belongs to the serine protease inhibitor (serpin) family but 
unlike other serpins, α2-AP has an extensive C-terminal sequence of approximately 50 
amino acids that contains a number of lysine residues that are important for plasmin 
inhibition and plasmin (ogen) binding [120]. In addition, the C-terminal region of α2-AP 
contains an RGD tri-peptide sequence (Arg426-Gly-Asp) that is essential for cell 
recognition and adhesion [121]. Using the RGD sequence, the C-terminal region of α2-
AP binds to endothelial cell integrins. With the aid of X-ray structure, the C-terminal of 
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α2-AP is shown to be positioned in the proximity of the reactive loop and binds strongly 
to the K1 and K4 domains of plasmin increasing the inhibitory effect of α2-AP [122-124].  
Table 5: Properties of α2-antiplasmin 
 Met-α2AP Asn-α2AP 
Molecular weight [113, 
114] 
67 KDa 64 KDa 
Amino acids [113, 114] 464 452 
N-terminal Methionine Asparagine 
Percentage [113, 114] 30% 70% 
Binding to fibrinogen [118] Slower 3-13 times faster 
 
Human α2-AP regulates the fibrinolysis process in three ways [125]: 
I. Inactivates plasmin by forming a complex with it [126]. 
II. Prevents plasminogen adsorption to fibrin surface [127, 128]. 
III. Increases fibrin resistant to fibrinolysis by cross-linking fibrin with the aid of 
FXIII [129-131].  
In plasma, α2-AP inactivates plasmin rapidly with a second order reaction rate of 2x10
-7
 
mol
-1
 s
-1
 [132]. The reaction of Lys448 and Lys464 residues in the carboxyl-terminal of 
α2-AP with 1-3 kringles of plasmin (ogen) changes the conformation of the Ser741 of 
plasmin which then binds to Arg376 of α2-AP to form the inactive irreversible plasmin-
α2AP complex [133, 134]. Moreover, Lys groups in both α2-AP and fibrin bind to the 
same active sites in plasminogen thereby α2-AP competitively inhibits the binding of 
plasminogen to fibrin. Free plasmin generated by tissue-type plasminogen activator in 
plasma has a short half-life (~0.1 sec) due to the rapid inactivation by α2-AP, while 
plasmin produced in fibrin surface has a relatively longer half-life (~10 to 100 sec) 
15 
 
because it is only slightly inactivated by α2-AP [135]. This indicates the importance of 
prior incorporation of α2-AP into fibrinogen for effective inhibition of fibrinolysis.  
The cross-linking of α2-AP to fibrinogen by FXIII is the most effective way to 
inhibit endogenous fibrinolysis concurrent with fibrin formation and caused by activation 
of plasminogen-bound to fibrin [130, 136]. The cross-linking reaction occurs between 
either Gln14 of Met-α2AP or Gln2 of Asn-α2AP and Lys303 of α-chain of fibrin. FXIII 
catalyzes transfer of acyl groups donated by α2-AP to the acceptor amine groups of 
fibrinogen. The cross-linking reaction of α2AP with fibrinogen progress rapidly to 
reaches a maximum plateaus with only 20-30% of the available Lys303 active sites being 
occupied [137-139]. This limited reactivity suggests that the reaction equilibrium favors 
dissociation of the cross-linked product or Lys303 active sites are unavailable for cross-
linking reaction [140]. Asn-α2AP cross-links fibrinogen 3-13 times faster than Met-α2AP. 
Consequently, the ratio of the two forms of α2-AP plays a critical role in the regulation of 
fibrinolytic process [118].  
While the molecular mechanism of plasmin inhibition in solution is well 
understood, the inhibition of plasmin on the fibrin surface still requires further studies. In 
addition to plasmin inactivation, α2-AP also inhibits tissue-type plasminogen activator 
(TPA) and urokinase. The physiological importance of α2-AP is best characterized by 
issues encountered by individuals deficient in this inhibitor.  These patients experience 
uncontrolled fibrinolysis and recurrent severe hemorrhagic disorder [141, 142].  
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Previous studies have shown that the content of α2-AP in plasma-derived 
fibrinogen is substantial (1.2-1.8 moles α2-AP per mole pdFI), and that native FXIII 
catalyze its cross-linking in circulation [143].  
Fibronectin 
 
Fibronectin is the second most abundant protein within the extracellular matrix 
(ECM) mediating its interactions with variety of cells. Fibronectin is multifunctional 
glycoprotein exists in a soluble form in plasma, and in an insoluble form in the ECM. 
Plasma fibronectin (pdFN) is synthesized by hepatocytes and secreted into plasma where 
it circulates at a concentration of approximately 300-400 µg/ml [144]. Cellular 
fibronectin (cFN) is composed of covalently cross-linked multimers and synthesized by 
different cell types including fibroblasts, endothelial cells, chondrocytes, synovial cells, 
and myocytes [145].  
Fibronectin is composed of two very similar polypeptides with a molecular 
weight of 220-250 kDa [146-148]. The polypeptides are linked by inter-chain disulfide 
bonds located close to the C-terminal region forming a dimer molecule [149, 150]. Using 
rotary shadowing electron microscopy the polypeptides appear as flexible extended V-
shaped molecules or compact globular molecules [151]. Each polypeptide is made of 
multiple homologous modules called type I, II, and III (F1, F2, and F3) in series [152-
154]. There are 12 type I modules, two type II modules, and 15-17 type III modules, 
which together accounts for ~90% of the fibronectin sequence. Type I modules contain 
~45 amino acids held together by two disulfide bonds and located in the amino and 
17 
 
carboxyl termini regions of each subunit. Type II modules are composed of ~60 amino 
acids linked by two disulfide bonds and localized in the gelatin binding domain of the 
subunit. Type III modules consists of ~90 amino acids that are clustered together in the 
middle of the subunit and does not contain disulfide bonds [155]. The N-terminal region 
of fibronectin consist of five type I modules whereas the C-terminal contains three type I 
modules.  
Fibronectin contains binding sites for different molecules that are localized along 
the length of the monomer enabling fibronectin to play an important role in many 
physiological processes [156]. Because it’s rich in Arg-Gly-Asp tri-peptide sequences, 
fibronectin plays important roles in cell migration, growth, and differentiation [157]. 
Fibronectin incorporated into fibrin by FXIIII mediates interaction of fibrin with cells or 
platelets during clot formation [158-160]. Bound fibronectin forms a three-dimensional 
matrix at the wound site that attracts different cell types and extracellular matrix proteins 
[161]. F1 (1-5) contains binding sites for heparin, fibrin, and cell surface proteins for 
pathogenic bacteria such as streptococcus dysgalactiae that play a putative mechanism for 
host by microorganism [162].   
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PURIFICATION OF FIBRINOGEN FROM HUMAN PLASMA 
 
We are employing a combination of physical and chemical precipitation methods 
to purify relatively large amount of fibrinogen from human plasma for the purpose of 
fibrin based bandages and expanding hemostatic foams. Virally inactivated fibrinogen 
was isolated from human plasma using cryoprecipitation followed by ethanol or 
ammonium sulfate precipitation. Fig 2 shows the major steps of the fibrinogen production 
procedure. The aim of this study was to evaluate the ability of ethanol and ammonium 
sulfate precipitation approaches to eliminate solvent detergent. We also estimated the 
amount of fibronectin, factor XIIIA, factor XIIIB, and α2-antiplasmin in plasma 
fibrinogen purified by the two different chemical precipitation methods.   
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Materials and Methods 
 
Materials 
 
All reagents of highest purity were purchased from Sigma Chemical Company (St. Louis, 
MO) unless otherwise noted. Human plasma was donated by the U.S. Army Materials 
Command (Fort Detrick, MD). Human plasma fibrinogen depleted of fibronectin, 
plasminogen, and von Willebrand Factor was purchased from Enzyme Research 
Laboratories (South Bend, IN). Recombinant human thrombin (rFIIa) was purchased 
from ZymoGenetics, Inc. (Seattle, WA). Human FXIII was bought from Enzyme 
Research Laboratories. Human α2-AP was obtained from Haematologic Technologies 
Inc. (Essex Junction, VT). Anti-mouse fibronectin monoclonal IgG1 antibody was 
obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-human FXIIIB 
monoclonal antibody was purchased from Green Mountain Antibodies (Burlington, VT). 
Anti-human FXIIIA polyclonal antibody was bought from US Biologicals. Anti-human 
α2AP polyclonal antibody HRP was bought from US Biologicals. Anti-mouse IgG (whole 
molecule) peroxidase conjugate and anti-sheep IgG peroxidase conjugate were obtained 
from Sigma Chemical Company. Activated recombinant human factor XIII was purified 
in our lab.  Thromboelastography (TEG) disposable cups and pins were bought from 
Haemoscope (Niles, IL). 
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Figure 2: Fibrinogen purification procedure 
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Preparation of Cryoprecipitate 
Fifteen units of human plasma (12.65 liters) frozen at -80 °C were thawed slowly 
for two days at 4 °C. The resulting mixture was centrifuged in a Sorvall RC-5C Plus 
Superspeed Centrifuge (Kendro Laboratory, Newtown, CT) at 4000 rpm for 20 min at 4 
°C. The supernatant was stored at -80 °C for future fibronectin purification. The 
fibrinogen-rich cryoprecipitate was re-suspended in a re-suspension buffer containing 20 
mM tris-base, 55 mM sodium citrate, 27 mM lysine, PH 6.8. The solution was stirred 
overnight at room temp. Viral inactivation was carried out using two different types of 
solvent detergent. Part of the re-suspended cryoprecipitate was adjusted to 0.3% (V/V) 
TNBP and 1% (V/V) Tween 80 while the other portion was subjected to 0.15%  (V/V) 
TNBP and 0.5% (V/V)  Triton X-100 and the two solutions were stirred overnight at 
room temp.  
Ethanol Precipitation  
 
Ethanol precipitation method was conducted by slightly modifying a previously 
described method [52]. Briefly, the two types of solvent detergent treated solutions were 
cooled to ~4 °C on ice then adjusted to 10% ethanol. Samples were incubated on ice 
overnight then centrifuged in a Sorvall RC-5C Plus Superspeed Centrifuge at 4000 rpm at 
4 °C for 20 min. The supernatant was discarded and the pellet was solubilized in re-
suspension buffer. A second 10% ethanol precipitation step was carried out at ~4 °C for 
two hours on ice. The resulting pellet was solubilized in re-suspension buffer then 
dialyzed versus dialysis buffer containing 20 mM sodium citrate, 100 mM sodium 
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chloride, PH 7.4 at room temp. The dialyzed protein was collected and centrifuged for 20 
min at 4000 rpm at 25 °C. Purified fibrinogen was stored in aliquots at - 80 °C.  
Ammonium Sulfate Precipitation  
 
The virally-inactivated cryo solutions were chilled to ~4 °C on ice then adjusted 
to 1 M ammonium sulfate by adding a 4 M stock solution. Samples were incubated on ice 
overnight then centrifuged at 4000 rpm at 4 °C for 20 min. The precipitate was re-
suspended in re-suspension buffer at room temp then chilled to ~4 °C on ice. A second 
ammonium sulfate precipitation was done and the pellet was solubilized in re-suspension 
buffer then dialyzed against dialysis buffer. The isolated protein was centrifuged for 20 
min at 4000 rpm at 25 °C then frozen at -80 °C.  
BCA Standard and Spectrophotometry 
 
Total protein concentration was determined by spectrophotometric measurement 
at 280 nm as well as BCA Standard procedure using bovine serum albumin as standard. 
Evaluating Purified pdFI by SDS-PAGE  
 
The purity of the isolated fibrinogen was examined by sodium dodecylsulfate-
polyacrylamide (SDS-PAGE) gel electrophoresis. Samples were analyzed on 4-12% 
NuPAGE Bis-Tris Mini Gels (Life Technologies, Carlsbad, CA) under reducing 
condition. Samples were treated with SDS sample buffer and reducing agent, both 
obtained from Invitrogen (Carlsbad, CA). After 10 minutes incubation at 74 °C, samples 
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were loaded onto the gel and run using 2-(N-morpholino) ethanesulfonic acid (MES) for 
one hour at 200 volts. Gels were stained with colloidal blue (Invitrogen, Carlsbad, CA).  
Evaluating Clottability of pdFI by Thromboelastography 
 
Thromboelastography (TEG) Hemostasis system 5000 series (Haemoscope 
Corporation, Niles, IL) was used to evaluate the ability of purified fibrinogen to form a 
clot. pdFI (concentrations of 9 or 4.5 mg/ml) were placed in a TEG cup, which is kept at 
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C by the instrument. rFXIIIa (concentration of 0.36 mg/ml) was added. CaCl2 
(concentration of 12 mM) and Ringer solution (155 mM NaCl, 5 mM KCl, 2 mM CaCl2, 
and 1 mM MgCl2) were added followed immediately by rFIIa (concentration of 105.6 
U/ml) to trigger clot formation. The TEG analyzer collected clot parameters such as the 
time to reach 2 mm clot strength (R), the time to reach 20 mm clot strength (K), and the 
maximum clot strength (MA) every five seconds for 30 minutes. The data was collected 
and analyzed in Microsoft Excel. 
Estimating pdFXIIIA, pdFXIIIB, α2-AP, and pdFN by Western Blot  
 
The contents of pdFXIIIA, pdFXIIIB, α2-AP, and pdFN on the isolated fibrinogen 
were estimated by quantitative western blot analysis. Samples were analyzed on 4-12% 
NuPAGE Bis-Tris Mini Gels (Life Technologies, Carlsbad, CA) under reducing or non-
reducing condition. Gels were electroblotted onto polyvinylide fluoride (PVDF) 
membranes (Millipore, Billerica, MA) for 30 min at 25 volts. Blots were blocked in 50 
ml 5% casein in TBST then incubated for 30 minutes with the following antibodies: (a) 
anti-human FXIIIA polyclonal antibody (US Biologicals, Swampscott, MA), (b) anti-
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human FXIIIB monoclonal antibody (Green Mountain Antibodies, Burlington, VT), (c) 
anti-human α2AP polyclonal antibody HRP (US Biologicals), (d) anti-mouse fibronectin 
monoclonal IgG1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA). Blot developed 
with anti-human FXIIIA polyclonal antibody was subsequently detected with anti-sheep 
IgG peroxidase conjugate (Sigma). Blots developed with anti-human FXIIIB monoclonal 
antibody and anti-mouse fibronectin monoclonal IgG1 antibody were probed with anti-
mouse IgG peroxidase conjugate (Sigma). Blots were visualized with DAB/Metal 
concentrate and stable peroxide substrate buffer (Thermo Scientific, Rockford, IL) or 
chemiluminescence using Immun-Star HRP enhancer and peroxide buffer (Bio-Rad 
Laboratories, Hercules, CA). The quantity of pdFXIIIA, pdFXIIIB, pdFN, and α2-AP 
were determined from the immunoblot of each material using Imagej (National Institute 
of Health) or Adobe Photoshop Elements (Adobe Systems Incorporated).  
Results  
 
Evaluating Purified pdFI by SDS-PAGE  
 
SDS-PAGE analysis [Fig 3] conducted under reducing condition showed that 
pdFI purified by cryoprecipitation (lane 5), first ethanol precipitation (lane 6), second 
ethanol precipitation (lane 7), first ammonium sulfate precipitation (lane 8), and second 
ammonium sulfate precipitation (lane 9) all exhibit three distinct bands with apparent 
molecular weights of ~67, 54, 47 kDa likely corresponding to the well-established α, β, 
and γ chains of fibrinogen. Lanes 5, 6, 7, 8, and 9 also revealed a minor band at higher 
molecular weight of ~220 kDa characteristic of fibronectin monomer. pdFI isolated by 
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ethanol and ammonium sulfate precipitation contain two faint bands at ~80 and 120 kDa. 
In addition to the bands at ~80 and 120 kDa, pdFI purified by cryoprecipitation possesses 
additional faint bands. 
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Figure 3: Reduced gel evaluation of purified pdFI. 
Samples were analyzed on 4-12% SDS-PAGE and stained with 
colloidal blue. Lane 1 is molecular weight marker. Lane 2 is human 
fibrinogen (Enzyme Research). Lane 3 is human fibronectin (Enzyme 
Research). Lane 4 is blank. Lane 5 is pdFI purified by cryoprecipitation. 
Lanes 6 and 7 are pdFI purified by first and second AS precipitation, 
respectively. Lanes 8 and 9 are pdFI purified by first and second EtOH 
precipitation, respectively. 
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Evaluating Clottability of pdFI by Thromboelastography 
 
The viscoelastic and mechanical properties of clot formed by plasma fibrinogen 
purified by cryoprecipitation, ethanol, and ammonium sulfate precipitation were 
evaluated by thromboelastography [Fig 4]. It took 10 seconds to initiate clot formation 
after rFIIa was added to pdFI isolated by cryoprecipitation, ethanol, and ammonium 
sulfate precipitation [Table 6]. The maximal strength of clot developed by pdFI purified 
by the first ethanol precipitation (1x) was 3267.70 ± 9.05 dynes/sec compared to 3278.9 
± 829.58 dynes/sec for clot formed by pdFI purified by the second ethanol precipitation 
(2x). pdFI isolated by the second ammonium sulfate precipitation (2x) resulted in clot 
with maximal strength of 5811.7 ± 139.44 dynes/sec whereas pdFI purified by the first 
ammonium sulfate precipitation (2x) formed clot with maximal strength of 2483.75 ± 
167.09 dynes/sec. Clot developed from pdFI purified by the second ammonium sulfate 
precipitated fibrinogen has the highest maximal strength (5811.7 ± 139.44). Clot 
formation was inhibited in the solvent detergent (TNBP and Triton X-100) treated pdFI 
purified by a single ammonium sulfate precipitation (Fig 5). 
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Figure 4: Thromboelastography analysis of the clottability of isolated 
fibrinogen. Change in maximal strength of clot developed by pdFI (4.5 mg/ml) activated 
by rFIIa (105.6 U/ml) was recorded over time. 
 
 
 
Table 6: Parameters of clot formed by purified fibrinogen 
Protein 
R 
(sec) 
K 
(sec) 
Angle 
(deg) 
MA 
(mm) G (d/sc) 
pdFI (Enzyme Research) 10 50 84.2 43.3 3822.53 
pdFI Purified By EtOH Precipitation (1x) 10 50 83.7 39.6 3267.70 
pdFI Purified By AS Precipitation (1x) 10 50 82.9 33.2 2483.75 
pdFI Purified By EtOH Precipitation (2x) 10 50 83.0 39.3 3278.9 
pdFI Purified By AS Precipitation (2x) 10 50 85.5 53.8 5811.7 
pdFI Purified By Cryoprecipitation  -2825 -225 -26.5 -2.2 -110.6 
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Figure 5: Thromboelastography analysis of the clottability of fibrinogen 
purified by a single ammonium sulfate precipitation. Clot was formed by treating 
plasma fibrinogen (9 mg/ml) with thrombin (105.6 U/ml). 
 
Estimating Amounts of pdFXIIIA by Densitometry  
 
Anti-human FXIIIA western blot analysis was conducted to estimate the 
percentage of FXIIIA in pdFI isolated by the three purification techniques [Fig 6]. pdFI 
purified by cryoprecipitation (lane 6), ammonium sulfate precipitation (lane 7), and 
ethanol precipitation (lane 8) show bands corresponding to the known molecular weight 
of pdFXIIIA. Using densitometry by Imagej, the percentages of FXIIIA in pdFI purified 
by cryoprecipitation, ethanol, and ammonium sulfate precipitation were 0.652%, 0.781%, 
and 0.683% respectively.  
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Figure 6: Western blot and densitometry by Imagej analysis of pdFXIIIA. 
Samples were analyzed under non-reducing condition then developed with anti-FXIIIA Pab 
and detected with anti-sheep IgG Peroxidase. Lane 1 is molecular weight marker. Lanes 2, 3, 
4, and 5 are 0.063, 0.125, 0.25, and 0.5 µg purified pdFXIII respectively. Lane 6 is pdFI 
purified by cryoprecipitation. Lane 7 is pdFI purified by ammonium sulfate precipitation. Lane 
8 is pdFI purified by ethanol precipitation.  
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Estimating Amounts of pdFXIIIB by Densitometry 
 
The amounts of FXIIIB in pdFI precipitated by the three purification methods 
were calculated from the anti-human FXIIIB western blot analysis [Fig 7]. pdFI isolated 
by cryoprecipitation (lane 7), ammonium sulfate precipitation (lane 8), and ethanol 
precipitation (lane 9) show a band characteristic of the known molecular weight of 
pdFXIIIB. Densitometric measurement of the bands revealed that cryoprecipitation, 
ammonium sulfate, and ethanol precipitation pdFI contain 0.329%, 0.809%, and 0.481% 
respectively. 
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Figure 7: Western blot and densitometry by Imagej analysis of pdFXIIIB. 
Samples were analyzed under non-reducing condition and developed with anti-FXIIIB 
Mab then detected with anti-mouse IgG peroxidase. Lane 1 is molecular weight marker. 
Lanes 2, 3, 4, and 5 are 0.063, 0.125, 0.25, and 0.5 µg purified pdFXIII respectively. 
Lane 6 is blank. Lane 7 is pdFI purified by cryoprecipitation. Lane 8 is pdFI purified by 
ammonium sulfate precipitation. Lane 9 is pdFI purified by ethanol precipitation. 
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Estimating Amounts of α2-AP by Densitometry   
 
The content of α2-AP in the purified pdFI was determined by anti-human α2AP 
western blot analysis [Fig 8]. pdFI isolated by cryoprecipitation (lane 6), ammonium 
sulfate (lane 7), and ethanol (lane 8) precipitation exhibit a minor band at ~62 kDa 
representing the molecular weight of α2-AP. By employing densitometry, pdFI purified 
by cryoprecipitation, ammonium sulfate, and ethanol precipitation contain 0.184%, 
0.493%, and 0.254% α2-AP. 
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Figure 8: Western blot and densitometry by Imagej analysis of α2-AP. 
Samples were analyzed under reducing condition and developed with anti- α2AP Pab 
HRP. Lane 1 is molecular weight marker. Lanes 2, 3, 4, and 5 are 0.013, 0.025, 0.05, 
and 0.1 µg purified α2-AP respectively. Lane 6 is pdFI purified by cryoprecipitation. 
Lane 7 is pdFI purified by ammonium sulfate precipitation. Lane 8 is pdFI purified by 
ethanol precipitation. 
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Estimating Amounts of pdFN by Densitometry   
 
Anti-human FN western blot analysis was done to estimate the quantity of FN 
purified with pdFI [Fig 9]. pdFI purified by cryoprecipitation (lane 7), ammonium sulfate 
(lane 8), and ethanol precipitation (lane 9) show bands at ~220 kDa corresponding to 
fibronectin monomer. Densitometry by Adobe Photoshop Elements was employed to 
calculate the percentage of FN in pdFI isolated by cryoprecipitation (3.18%), ammonium 
sulfate precipitation (8.09%), and ethanol precipitation (3.98%).  
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Figure 9: Western blot and densitometry by Imagej analysis of pdFN. 
Samples were analyzed under reducing condition and developed with anti-mouse 
fibronectin monoclonal IgG1 then detected with anti-mouse IgG peroxidase. Lane 
1 is molecular weight marker. Lanes 2, 3, 4, and 5 are 0.25, 0.5, 1, and 2 µg 
purified pdFN respectively. Lane 6 is blank. Lane 7 is pdFI purified by 
cryoprecipitation. Lane 8 is pdFI purified by ammonium sulfate precipitation. Lane 
9 is pdFI purified by ethanol precipitation.  
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DISCUSSION 
 
Various approaches have been developed to isolate fibrinogen from plasma 
sources. These methods include cryoprecipitation, centrifugation, ultrafiltration, 
chromatography, and chemical precipitation. We isolated a solvent detergent treated 
fibrinogen from human plasma using cryoprecipitation followed by ammonium sulfate or 
ethanol precipitation. Fibrinogen isolated by the three purification methods is highly 
pure. To determine the effectiveness of purified plasma fibrinogen to form clots, we 
measured clottability of fibrinogen using thromboelastography. Our study showed that 
clot formed from plasma fibrinogen produced by the repeated ammonium sulfate 
precipitation has the highest maximal strength.  
Based on the purification method, fibrinogen removed from plasma contains 
various amounts of fibronectin, factor XIII, alpha2-antiplasmin, plasminogen, and other 
plasma proteins. We estimated the quantities of fibronectin, factor FXIIIA, factor FXIIIB, 
and α2-AP in the plasma fibrinogen isolated by three purification procedures. Plasma 
fibrinogen obtained by ammonium sulfate precipitation was found to contain increased 
ratios of FXIIIA, FXIIIB, FN, and α2-AP to fibrinogen than the starting cryoprecipitate. 
Plasma fibrinogen from ethanol precipitation also contains higher ratios of FXIIIA, 
FXIIIB, α2-AP, and FN to fibrinogen than the original cryoprecipitate. This indicates that 
chemical precipitation may preserve the binding of FXIIIA, FXIIIB, FN, and α2-AP to 
fibrinogen during the purification process.  
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Viral inactivation was achieved by using two different types of solvent detergent 
mixtures: (1) 0.3% TNBP and 1% Tween 80, (2) 0.15% TNBP and 0.5% Triton X-100. 
Since the presence of solvent detergent inhibits clot formation, we utilized 
thromboelastography to evaluate the effectiveness of ethanol and ammonium sulfate 
precipitation to remove the solvent detergent. While purifying a solvent detergent treated 
fibrinogen from human plasma, Burnouf-Radosevich et al [52] applied a second ethanol 
precipitations to further remove the solvent detergent. However, we showed that clots 
formed from fibrinogen isolated by first and second ethanol precipitation have similar 
maximal strength. This indicates that a single ethanol precipitation step is capable of 
eliminating the solvent detergent.  A single ammonium sulfate precipitation partially 
removed the mixture 0.3% TNBP and 1% Tween 80 but not the mixture 0.15% TNBP 
and 0.5% Triton x-100. Thus, a second ammonium sulfate precipitation is required for the 
complete elimination of the solvent detergent mixture TNBP and Triton X-100. 
Together the data presented in this thesis indicate that the combination of 
cryoprecipitation and successive ammonium sulfate precipitations results in the 
fibrinogen with the strongest clot forming activity. The bases for the increased strength 
has not been determined but is likely due to the increased ratios of associated proteins, 
particularly fibronectin in the ammonium sulfate derived material. 
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